Based on animal studies, kidney function should be monitored in patients taking casimersen.
- TRADE NAME: Amondys 45 (Sarepta Therapeutics)
- INDICATIONS: Duchenne muscular dystrophy
- CLASS: Antisense oligonucleotide
- HALF-LIFE: 3.5 hours
- FDA APPROVAL DATE: 02/25/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no human or animal data available to assess the use of casimersen during pregnancy.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
